Compare Bristol-Myers Squibb Co (BMY) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.81 (market cap $132.45B), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $49.67. The key difference: Bristol-Myers Squibb Co pays a 3.89% dividend while Vanguard Sht-Term Inflation-Protected Sec Idx ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Vanguard Sht-Term Inflation-Protected Sec Idx ETF nearer its low. Which is the better fit depends on your goals.
| BMY | VTIP | |
|---|---|---|
Market Cap | $132.45B | — |
Sector | Health | — |
52-Week High | $65.89 | $50.75 |
52-Week Low | $42.60 | $49.39 |
Enterprise Value | $166.44B | — |
Dividend Yield | 3.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.72, up 0.89% today, with a bullish technical signal and strong earnings beats in recent quarters. The company shows robust profitability with a net income margin of 18.87% and ROE of 46.7%, though debt levels have risen. Recent news highlights a $2.3 billion manufacturing investment and merger speculation with AstraZeneca, driving investor interest.
BMY presents a mixed outlook: valuation metrics like P/E of 14.26 appear attractive, and analyst consensus targets $68.56. However, risks include patent expirations, high debt, and volatile cash flows. The stock's near-term performance hinges on merger developments and execution of growth initiatives amid competitive pressures.
VTIP, the Vanguard Short-Term Inflation-Protected Securities ETF, trades at $49.67, up 0.08% with a bullish technical signal. The ETF focuses on short-term Treasury Inflation-Protected Securities, offering inflation hedging. Recent news highlights institutional buying and inflation concerns, with a dividend declared for July 2026. Technical indicators show mixed signals but overall positive momentum.
Outlook: VTIP provides inflation protection amid rising prices, with potential returns around 3.8% based on current inflation. Risks include interest rate volatility and Fed policy uncertainty. It suits investors seeking low-duration, inflation-linked income, but may underperform if inflation subsides unexpectedly.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →
